摘要
目的:观察西酞普兰联合利培酮治疗难治性抑郁症的近期临床疗效,探讨提高难治性抑郁症近期临床疗效的药物治疗方案方法:选择难治性抑郁症患者86例,随机均分为对照组与观察组,对照组给予常规西酞普兰治疗,观察组给予西酞普兰联合利培酮治疗,比较两组患者治疗第2周、第4周、第6周汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评分,比较两组患者治疗第6周的临床疗效。结果:观察组近期临床疗效好于对照组,HAMD评分、HAMA评分和临床疗效比较,差异具有统计学意义(P<0.05);TESS评分比较,差异无统计学意义(P>0.05)。结论:药物治疗难治性抑郁症时,应选择西酞普兰联合利培酮治疗,可提高近期临床疗效,且不加重用药不良反应。
Objective： To observe the recent clinical effect of citalopram combined risperidone in the treatment of refractory depression and research the drug treatment programs to improve the recent clinical effect.Method： Collect 86 refractory depression patients,43 patients were divided into the control group treated by citalopram,43 patients were divided into the observation group treated by citalopram combined risperidone,then compare the HAMD score,HAMA score and TESS score after two weeks＇,four weeks＇ and six weeks＇ treatment,compare the clinical effect after six weeks＇ treatment.Result： The observation group＇s recent clinical effect was better than the control group＇s,there was a statistical significant（P0.05） in the HAMD score,HAMA score and clinical effect,there was no statistical significant（P0.05） in the TESS score.Conclusion： When we treat refractory depression patients by drug,we should choose citalopram combined risperidone,it could improve the recent clinical effect and don＇t increase the adverse drug reaction.
出处
《现代生物医学进展》
CAS
2011年第14期2674-2676,共3页
Progress in Modern Biomedicine
关键词
西酞普兰
利培酮
难治性
抑郁症
近期疗效
Citalopram
Risperidone
Refractory
Depression
Recent clinical effect
